ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 219 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q3 2023. The put-call ratio across all filers is 0.74 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $393 | -82.6% | 11 | -77.6% | 0.00% | -100.0% |
| Q2 2023 | $2,261 | +52.4% | 49 | +32.4% | 0.00% | – |
| Q1 2023 | $1,484 | +146.5% | 37 | +184.6% | 0.00% | – |
| Q4 2022 | $602 | – | 13 | +8.3% | 0.00% | – |
| Q3 2022 | $0 | -100.0% | 12 | +20.0% | 0.00% | – |
| Q2 2022 | $1,000 | -50.0% | 10 | -61.5% | 0.00% | -100.0% |
| Q4 2021 | $2,000 | +100.0% | 26 | +116.7% | 0.00% | – |
| Q3 2021 | $1,000 | – | 12 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Abingworth LLP | 38,100 | $2,928,000 | 1.67% |
| Opaleye Management Inc. | 80,000 | $6,149,000 | 1.59% |
| HIGHLINE CAPITAL MANAGEMENT, L.P. | 410,000 | $31,517,000 | 1.06% |
| Opus Point Partners Management, LLC | 6,311 | $485,000 | 1.05% |
| SECTOR GAMMA AS | 68,015 | $5,228,000 | 0.87% |
| Capital Impact Advisors, LLC | 27,074 | $2,061,000 | 0.76% |
| FORTALEZA ASSET MANAGEMENT INC/ | 1,130 | $87,000 | 0.71% |
| CAPITAL INTERNATIONAL LTD /CA/ | 46,957 | $3,610,000 | 0.63% |
| Virtus ETF Advisers LLC | 8,794 | $676,000 | 0.60% |
| Rock Springs Capital Management LP | 200,000 | $15,374,000 | 0.59% |